Omalizumab in chronic spontaneous urticaria treatment: Real life experiences

ENGİN, BURHAN; Celik, Ugur; BİRBEN, Aslıhan; AŞKIN, ÖZGE; KUTLUBAY, ZEKAYİ; SERDAROĞLU, SERVER

doi:10.4274/turkderm.galenos.2019.90001

Omalizumab in chronic spontaneous urticaria treatment: Real life experiences

ENGİN B., Celik U., BİRBEN A. Ö., AŞKIN Ö., KUTLUBAY Z., SERDAROĞLU S.

TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, cilt.53, sa.4, ss.145-149, 2019 (ESCI, Scopus, TRDizin)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 53 Sayı: 4
Basım Tarihi: 2019
Doi Numarası: 10.4274/turkderm.galenos.2019.90001
Dergi Adı: TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY
Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
Sayfa Sayıları: ss.145-149
İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

Background and Design: Urticaria is an intensely pruritic dermatologic disorder characterized by temporary erythematous and edematous lesions. Immunoglobulin E (IgE), mast cells, and histamine play a major role in its pathogenesis. H-1 antihistamines are the basis of the treatment, but they may not be sufficient for some cases. The latest guidelines advise using omalizumab, anti-IgE monoclonal antibody, for patients with refractory urticaria. Our aim was to evaluate the efficacy and safety of omalizumab in patients with chronic spontaneous urticaria and share the real-life experiences in our patients.